Testing two drugs together for gliomas that came back in kids and young adults
Original title: Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is an early test in people to check safety and find the right dose.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This trial tests whether two drugs used together work better against a glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are graded 1 to 4 by how fast they tend to grow. See the glossary that has come back.
Who this trial is for. This trial is for children and young adults whose glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are graded 1 to 4 by how fast they tend to grow. See the glossary has come back. It tests two drugs, trametinib and everolimus, given together.
Where it stands. The trial is looking at side effects and the best dose of the two drugs. It has not reported results yet. The answer is not in.
What this means, and what it doesn't
What it could mean: Trametinib targets a protein in cells called MEK. Everolimus may block another pathway that helps tumors grow. The two together may work better than either drug alone for low and high grade gliomas. If this sounds like your situation, you could ask your care team about it.
What it doesn't mean: A trial is a test, not a proven treatment. Being in one does not mean it will help you. It is not a promise of a cure.
Source: ClinicalTrials.gov, August 18, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.